Good things come in 3s — SugarCone Biotech DLL3, B7H3 and Her3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attackin...

quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue

www.sugarconebiotech.com/insights/goo...

AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’ UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug

news for #bioblue #biotech

www.theguardian.com/business/202...

and we provide some broader #biotech #bioblue context
www.sugarconebiotech.com/insights/pd1...

A bit more #bioblue #biotech #oncology news from aletabiotherapeutics.com - we've invented a remarkable way to boost the functionality of T Cell Engager proteins (TCE) by making tumor cells look more like an immune cell. The "engaged" T cells just LOVE the embrace. www.nature.com/articles/d43...

hey #bioblue --- in a time of simply ridiculous copycat drug development we found a few examples of real innovation. Part 1 - novel bispecific therapeutics in oncology. Posted only at sugarconebiotech.com.

www.sugarconebiotech.com/insights/nov...

Trump just added the CFIUS nail to the $XBI coffin.

#biotech #China #bioblue

CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options | CARGO Therapeutics, Inc. CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1 ; Company believes results do not support a competitive benefit-risk profile for patients. CARGO ...

CARGO runs aground

investors.cargo-tx.com/news-release...

#bioblue #bluebio #biotech

from an X thread
#biotech #bioblue

A BRIEF REVIEW OF DRUG DEVELOPMENT TARGETING THE LTβ/LTβR PATHWAY — SugarCone Biotech Companies mentioned: Biogen, Avalo Therapeutics, Pfizer, Roche, Mestag Therapeutics, Shanghai Junshi Bioscience Attempts to modulate the immune activity of the lymphotoxin beta pathway have been long...

The response of the our immune system to #cancer is complex ... and sometimes devastatingly inept. Can we use advanced immune-system hacking to destroy aggressive, advanced tumors? #bioblue #biotech

I have hope: www.sugarconebiotech.com/insights/a-b...

A BRIEF REVIEW OF DRUG DEVELOPMENT TARGETING THE LTβ/LTβR PATHWAY — SugarCone Biotech Companies mentioned: Biogen, Avalo Therapeutics, Pfizer, Roche, Mestag Therapeutics, Shanghai Junshi Bioscience Attempts to modulate the immune activity of the lymphotoxin beta pathway have been long...

Well here we go... The response of the human immune system to cancerous cells is complex and often devastatingly inept. Can we make ourselves more formidable using advanced immune-system hacking? I bet yes ... #bioblue #biotech #medblue

www.sugarconebiotech.com/insights/a-b...

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and...

In #celltherapy news, Roche to acquire Poseida for programs in blood cancers and autoimmunity/inflammation #bioblue #biotech

www.globenewswire.com/news-release...

Platelet factor 4–induced TH1-Treg polarization suppresses antitumor immunity The tumor microenvironment (TME) contains a number of immune-suppressive cells such as T helper 1–polarized regulatory T cells (TH1-Treg cells). However, little is known about the mechanism behind the...

just pondering stuff that doesn't work and here comes another chemokine - this one to control Tregs in anti-tumor immunity. As I don't believe Tregs do ANYTHING in anti-tumor immunity, I've gotta believe that PF4 targeting will be a bust
www.science.org/doi/10.1126/... also mousey. #bioblue

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma IPH6501, a CD20-targeted NK cell engager armed with non-alpha IL-2, shows preclinical efficacy and tolerability in B-NHL.

ok, neat. NK-based cell therapy and mutated-IL2 proteins that have failed clinically may work when brought together by an NK cell engager protein (also targeting CD20). www.science.org/doi/10.1126/...
Or maybe not, as this is MOUSE WORK and the translation to clinic is FRAUGHT... n.b. #bioblue

A lymphocyte chemoaffinity axis for lung, non-intestinal mucosae and CNS - Nature GPR25 and its ligand define the core chemoaffinity axis GPR25–CXCL17 of the integrated extraintestinal mucosal immune system, regulating how immune responses disseminate to non-intestinal barrier...

Cool "near-mucosal" immunity governed by a cool-kids couple (GPR25/CXCL17) revealed in "A lymphocyte chemoaffinity axis for lung, non-intestinal mucosae and CNS"

that's some keen #bioblue #immunity

www.nature.com/articles/s41...

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer - Nature Reviews Drug Discovery Members of the TNF superfamily (TNFSF) of ligands and their receptors have emerged as promising targets in the treatment of autoimmune diseases and cancer, with several biologics gaining FDA approval....

an #openaccess rvw on the development of therapeutics targeting the TNF/TNFR superfamilies. Everything you can imagine is in here www.nature.com/articles/s41... incl LTBR. NOTE: Pfizer's agonist tetravalent anti-LTBR recently terminated after n=4. I'll bet they hit liver tox! #biotech #bioblue

Aleta Biotherapeutics

also under #bioblue #biotech - A paper in Cell that is singing the Aleta Biotherapeutics technology anthem pubmed.ncbi.nlm.nih.gov/39504957/ building multi-domain solutions for solid tumors. Of course we also tune in a bit of immune system manipulation. aletabio.com